Gilead Sciences, Inc. $GILD Shares Bought by Fifth Third Bancorp

Fifth Third Bancorp grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.2% in the first quarter, HoldingsChannel reports. The fund owned 668,661 shares of the biopharmaceutical company’s stock after acquiring an additional 226,510 shares during the quarter. Fifth Third Bancorp’s holdings in Gilead Sciences were worth $93,191,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Paulson Wealth Management Inc. increased its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its position in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 71 shares in the last quarter. Davidson Trust Co. grew its holdings in Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the period. Alpha Cubed Investments LLC grew its holdings in Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Finally, Personal CFO Solutions LLC increased its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 83,000 shares of company stock valued at $10,824,500. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Leerink Partners reduced their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a report on Monday, July 6th. Daiwa Securities Group cut their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Finally, The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $159.04.

Gilead Sciences Price Performance

Shares of GILD traded down $5.01 during trading hours on Friday, hitting $129.83. 5,934,235 shares of the stock were exchanged, compared to its average volume of 7,886,756. The stock’s 50-day moving average price is $129.78 and its two-hundred day moving average price is $134.96. Gilead Sciences, Inc. has a 12-month low of $107.75 and a 12-month high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market cap of $161.19 billion, a price-to-earnings ratio of 17.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the firm posted $1.81 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.